Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Update

15 Feb 2024 07:00

RNS Number : 1219D
Checkit PLC
15 February 2024
 

15 February 2024

 

Checkit plc

("Checkit" or the "Group)

 

FY24 Trading Update

 

Checkit (AIM: CKT), the intelligent operations platform for the deskless worker, announces its unaudited trading update for the year ended 31 January 2024 ("FY24").

 

· Annual recurring revenue ("ARR"1) growth of 16% to £13.3m, in line with expectations

· Focus on path to profitability is anticipated to result in better than expected losses ("LBITDA"2) halving year-on-year to £3.4m

· Recurring revenues provide good visibility for future periods underpinned by a high net revenue retention3 of 111%

 

(£'m) Reported

Twelve months to

 

31 January 2024

31 January 2023

% Change

ARR

13.3

11.5

16%

 

 

 

 

Revenue

 

 

 

Recurring

11.2

9.6

+17 %

Non-recurring

0.8

0.7

+18 %

Total Group

12.0

10.3

+17 %

 

 

 

 

 

Kit Kyte, CEO of Checkit, commented: "The second half of the year has seen further progress on our stated strategy and our drive towards profitability. Our new AI enhanced products are, we believe, best in class and a step change ahead of what's currently available in the market. We will continue to focus on driving top-line growth in the business and look forward to FY25 with confidence."

 

Results

 

Revenue has grown by 17% to £12.0m, in line with market expectations despite the challenging global economy. Our 'Land and Expand' strategy of up-selling and cross-selling has generated growth from our existing customer base, whilst at the same time we have actively identified areas of expansion and opportunity both geographically and vertically. With recurring revenues now representing 93% of the total and our high net revenue retention of 111%, we have a sound base to pursue our drive towards profitability.

 

Our focus on gross margin expansion continues to deliver and we expect losses (adjusted LBITDA) to be better than expected and nearly halve for the year to £3.4m (2023: LBITDA of £6.4m) as we drive operational efficiencies and carefully manage costs across the business.

 

Our cash position at the end of year was £9.0m (31 July 2023: £12.8m), reflecting the 46% reduction in LBITDA and the strategic purchase of inventory to mitigate supply chain constraints in the market. We expect this position to unwind over the next 12-18 months, supporting further revenue growth.

 

Product Update

 

During the year, utilising the data we collect and new AI and ML tools, we have successfully added new functionality to our products that will allow our customers to deliver sustainability and energy saving initiatives and benefit from predictive maintenance of their assets. This is being actively trialled by one of our largest customers and we are confident that these developments will provide significant value to the Group and our customers.

 

We have continued to invest in our products and our markets and we are gaining traction geographically, with 26% of ARR now generated in the US, and as we develop our offerings to address new sectors, such as food manufacturing and R&D laboratories.

 

We will provide further detail on our product strategy and the path to profitability at the time of our FY24 Results announcement in April 2024.

 

The Group's management team will host a live webinar which will include an opportunity for questions at 14:00 (GMT) today. The webinar can be accessed via the news area of the website at https://www.checkit.net/news/ or by using this link:

https://www.investormeetcompany.com/checkit-plc/register-investor

 

NOTES

 

1. Annual Recurring Revenue ("ARR") is defined as the annualised value of contracted recurring revenue from subscription services as at the period end, including committed annual recurring revenue from new wins.

2. Adjusted LBITDA is the loss on operating activities before depreciation and amortisation, share based payment charges and non-recurring or special items. Analysts' Adjusted LBITDA expectations for FY24 were £3.6m.

3. Net revenue retention is defined as the amount of recurring revenue from existing customers retained over the period, excluding new wins in the last year.

 

 

For further information, please visit www.checkit.net or contact:

 

Checkit plc

Kit Kyte (Chief Executive Officer)

Greg Price (Chief Financial and Operations Officer)

+44 (0) 1223 643313

Singer Capital Markets (Nominated Adviser & Broker)

Shaun Dobson / Harry Gooden / James Fischer

+44 (0) 20 7496 3000

Tavistock (Financial PR)

Lulu Bridges / Katie Hopkins / Simon Hudson

+44 (0) 20 7920 3150

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGCGDDXUBDGSS
Date   Source Headline
29th Mar 20187:00 amRNSBulgin announces agreement with Arrow Electronics
6th Mar 20187:00 amRNSFSA successfully completes trials with Checkit
27th Feb 20187:00 amRNSHolding(s) in Company
16th Feb 20187:00 amRNSDisposal of Queensgate Nano
8th Feb 20187:00 amRNSTrading Statement
26th Jan 20183:37 pmRNSHolding(s) in Company
25th Jan 20185:58 pmRNSHolding(s) in Company
25th Jan 20187:00 amRNSAcquisition of IP in EET business
19th Jan 20183:45 pmRNSHolding(s) in Company
2nd Jan 20187:00 amRNSChange of Nominated Adviser and Broker
12th Dec 20177:00 amRNSGrant of Options
6th Dec 20174:02 pmRNSHolding(s) in Company
2nd Nov 20177:00 amRNSTrading Statement
23rd Oct 20174:16 pmRNSDirector/PDMR Shareholding
20th Oct 20177:00 amRNSDisposal of Sheen Instruments
16th Oct 201712:25 pmRNSHolding(s) in Company
27th Sep 20174:20 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSHalf-year Report
19th Sep 20177:00 amRNSContract Win
10th Aug 20177:00 amRNSTrading Update and Notification of Interim Results
31st Jul 20177:00 amRNSDisposal
13th Jul 201710:01 amRNSHolding(s) in Company
6th Jul 20173:00 pmRNSResult of AGM
6th Jul 20177:00 amRNSAGM Statement
16th Jun 201710:40 amRNSHolding(s) in Company
13th Jun 20177:57 amRNSHolding(s) in Company
6th Jun 201711:26 amRNSAnnual Report and Notice of AGM
18th May 20177:00 amRNSFinal Results
2nd May 20177:00 amRNSNotice of Results & AGM
27th Mar 20177:00 amRNSDisposal
8th Feb 20177:00 amRNSTrading Update
19th Jan 20177:00 amRNSDirector/PDMR Shareholding
14th Dec 20164:54 pmRNSHolding(s) in Company
13th Dec 20167:00 amRNSDirector/PDMR Shareholding
8th Dec 20169:00 amRNSReview of Operations
2nd Dec 20167:00 amRNSDisposal
30th Sep 20162:43 pmRNSDisposal of Carnation Designs
22nd Sep 20167:00 amRNSHalf-year Report
30th Aug 20169:52 amRNSHolding(s) in Company
1st Aug 20167:00 amRNSDirector/PDMR Shareholding
28th Jul 20163:56 pmRNSResult of AGM
28th Jul 20167:00 amRNSTrading Update
4th Jul 201610:40 amRNSLapsing of Options
30th Jun 20167:00 amRNSAnnual Report and Notice of AGM
9th Jun 20167:00 amRNSFinal Results
23rd May 20167:00 amRNSDisposal of Agar Scientific
18th May 20169:56 amRNSHolding(s) in Company
13th May 201610:06 amRNSHolding(s) in Company
20th Apr 20162:54 pmRNSDerivative Claim - Update
22nd Feb 20167:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.